Clinical trials of anti-infective agents in paediatrics

Guide to Paediatric Drug Development and Clinical Research

Volumn , Issue , 2010, Pages 170-177

  Lutsar, Irja ^a   Friedland, Ian ^b  

^a UNIVERSITY OF TARTU   (Estonia)

^b CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861528022     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/B978-380559363-2.31558-8     Document Type: Chapter

References (25)

1. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J Jr: The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infec-tious Diseases Society of America. Clin Infect Dis 2008;46:155-164.
2. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE: Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-1167.
3. Bradley JS, McCracken GH: Unique con-siderations in the evaluation of antibac-terials in clinical trials for pediatric community-acquired pneumonia. Clin Infect Dis 2008;47(suppl 3):S241-S248.
4. Glasziou PP, Del Mar CB, Sanders SL, Hayem M: Antibiotics for acute otitis media in children. Cochrane Database Syst Rev 2004;CD000219.
5. Sullivan A, Edlund C, Nord CE: Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001;1:101-114.
6. Metsvaht T, Oselin K, Ilmoja ML, Anier K, Lutsar I: Pharmacokinetics of penicil-lin g in very-low-birth-weight neonates. Antimicrob Agents Chemother 2007; 51:1995-2000.
7. Hines RN: The ontogeny of drug metab-olism enzymes and implications for adverse drug events. Pharmacol Ther 2008;118:250-267.
8. Alcorn J, McNamara PJ: Pharmacokinet-ics in the newborn. Adv Drug Deliv Rev 2003;55:667-686.
9. Karlsson MO, Lutsar I, Milligan PA: Pop-ulation pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009;53:935-944.
10. Craig WA: The hidden impact of anti-bacterial resistance in respiratory tract infection. Re-evaluating current antibi-otic therapy. Respir Med 2001;95(suppl A): S12-S19; discussion S26-S27.
11. Drusano GL: Antimicrobial pharmaco-dynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004;2: 289-300.
12. van den Anker JN, Pokorna P, Kinzig-Schippers M, Martinkova J, de Groot R, Drusano GL, Sorgel F: Meropenem phar-macokinetics in the newborn. Antimi-crob Agents Chemother 2009;53:3871-3879.
13. de Hoog M, Mouton JW, van den Anker JN: New dosing strategies for antibacte-rial agents in the neonate. Semin Fetal Neonatal Med 2005;10:185-194.
14. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N: 'Pharmacokinet-ics and safety of intravenous voricon-azole in children after single- or multi-ple-dose administration.' Antimicrob Agents Chemother 2004;48:2166-2172.
15. Kahlmeter G: Breakpoints for intrave-nously used cephalosporins in Enter-obacteriaceae-EUCAST and CLSI break-points. Clin Microbiol Infect 2008; 14(suppl 1):169-174.
16. Tod M, Jullien V, Pons G: Facilitation of drug evaluation in children by popula-tion methods and modelling. Clin Phar-macokinet 2008;47:231-243.
17. Rubino CM, Ambrose P, Cirincione B, Arguedas A, Sher L, Lopez E, Saez-Llorens X, Grasela DM: Pharmacokinet-ics and pharmacodynamics of gatifloxa-cin in children with recurrent otitis media: application of sparse sampling in clinical development. Diagn Microbiol Infect Dis 2007;59:67-74.
18. Doring G, Elborn JS, Johannesson M, de Jonge H, Griese M, Smyth A, Heijerman H: Clinical trials in cystic fibrosis. J Cyst Fibros 2007;6:85-99.
19. Brook I: A pooled comparison of cef-dinir and penicillin in the treatment of group a beta-hemolytic streptococcal pharyngotonsillitis. Clin Ther 2005;27: 1266-1273.
20. Wynn JL, Neu J, Moldawer LL, Levy O: Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis. J Perinatol 2009;29:79-88.
21. Drukker A, Guignard JP: Renal aspects of the term and preterm infant: a selec-tive update. Curr Opin Pediatr 2002;14: 175-182.
22. Mtitimila EI, Cooke RW: Antibiotic regi-mens for suspected early neonatal sep-sis. Cochrane Database Syst Rev 2004; CD004495.
23. Stoll BJ, Hansen NI, Higgins RD, Fan-aroff AA, Duara S, Goldberg R, Laptook A, Walsh M, Oh W, Hale E: Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J 2005;24:635-639.
24. Shani L, Weitzman D, Melamed R, Zmora E, Marks K: Risk factors for early sepsis in very low birth weight neonates with respiratory distress syndrome. Acta Paediatr 2008;97:12-15.
25. Ramachandrappa A, Jain L: Iatrogenic disorders in modern neonatology: a focus on safety and quality of care. Clin Perinatol 2008;35:1-34, vii.